{"url_path":"/sec/alks/8-k/2026-06-15/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Events.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-15","source_url":"https://www.sec.gov/Archives/edgar/data/1520262/0001193125-26-270280-index.html","accession_number":"0001193125-26-270280","cik":"0001520262","ticker":"ALKS","issuer_name":"Alkermes plc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1520262/0001193125-26-270280-index.html","primary_entity_key":"0001520262","primary_entity_name":"Alkermes plc."},"word_count":47,"has_tables":true,"body_markdown":"Item 8.01 Other Events.\n\n \n\nOn June 15, 2026, the Company announced that the U.S. Food and Drug Administration has granted orphan drug designation to alixorexton for the treatment of idiopathic hypersomnia, and the European Commission has granted orphan drug designation to alixorexton for the treatment of narcolepsy."}